Vedanta Biosciences doses first subject in Phase III C difficile prevention trial

Vedanta Biosciences doses first subject in Phase III C difficile prevention trial

Submitted by admin on May 22, 2024 - 11:24am
Source: 
Clinical Trials Arena
News Tags: 
Vedanta Biosciences
clinical trials
VE303
C. difficile
Headline: 
Vedanta Biosciences doses first subject in Phase III C difficile prevention trial
snippet: 

Vedanta Biosciences has dosed the first subject in Phase III RESTORATiVE303 clinical trial of VE303, a live biotherapeutic product candidate aimed at preventing recurrent C difficile infection (rCDI).

Do Not Allow Advertisers to Use My Personal information